Processing .....please wait.. 
The article has been forwarded.... 
Ranbaxy gets FDA nod for antidepressant
By SiliconIndia | Wednesday, 17 September 2003, 00:00 Hrs
MUMBAI: Ranbaxy Laboratories has announced that the company has received final approval from the US Food & Drug Administration (USFDA) to market Nefazodone Hydrochloride tablets (50mg, 100 mg, 150 mg, 200 mg and 250 mg.)
According to a release issued to the BSE today, Nefazodone Hydrochloride tablets are indicated for the treatment of depression.
"The product will be made available by Ranbaxy Pharmaceuticals Inc (RPI), a wholly-owned subsidiary of Ranbaxy, under the Ranbaxy label, on a nationwide basis in November," the release said quoting Jim Meehan, vice president (sales & marketing) of RPI
The company had earlier in the day announced the launch of Rosuvas (Rosuvastatin) - the most recent introduction among the drug class of statins.
According to a release issued to the BSE, statins are the most prescribed cholesterol reducing agent across the world.
"Rosuvas is the most aggressive therapy till date for lowering of LDL cholesterol, which also reduced triglycerides and raises HDL. The product has been introduced in India by Ranbaxy CV, the cardiovascular division of Ranbaxy," the release added.
According to a release issued to the BSE today, Nefazodone Hydrochloride tablets are indicated for the treatment of depression.
"The product will be made available by Ranbaxy Pharmaceuticals Inc (RPI), a wholly-owned subsidiary of Ranbaxy, under the Ranbaxy label, on a nationwide basis in November," the release said quoting Jim Meehan, vice president (sales & marketing) of RPI
The company had earlier in the day announced the launch of Rosuvas (Rosuvastatin) - the most recent introduction among the drug class of statins.
According to a release issued to the BSE, statins are the most prescribed cholesterol reducing agent across the world.
"Rosuvas is the most aggressive therapy till date for lowering of LDL cholesterol, which also reduced triglycerides and raises HDL. The product has been introduced in India by Ranbaxy CV, the cardiovascular division of Ranbaxy," the release added.
Don't Miss ( 1-5 of 20 )
Post your Comment
All form fields are required.
Write your comment now
Beautiful and dress selection, please go to Dresses
Sign Up for DailyDose and Read the Day's Highlights
Email:
 |
SiliconIndia:
About Us |
Contact Us |
Help |
Community rules |
Advertise with us |
Sitemap
News:
Technology |
Enterprise |
Tech Products |
Startups |
Finance |
Business |
Career |
Magazine |
Dailydose |
News archive
Career:
Jobs |
Companies |
Mentorship |
Videos |
Career blogs |
Training Institute |
Freshers
Online courses:
Web developer |
Java developer |
CCNA training |
SEO |
SAS |
SQL server 2005 |
J2EE
Education:
MBA |
MCA |
Engineering |
Overseas Education |
Internship
Life:
Jokes |
Bookstore |
Relocate |
Marketplace
Cities:
Startup |
Real estate |
Finance
Send your and help us continue to improve SiliconIndia
© 2012 SiliconIndia all rights reserved
© 2012 SiliconIndia all rights reserved